Institution
University of Perugia
Education•Perugia, Umbria, Italy•
About: University of Perugia is a education organization based out in Perugia, Umbria, Italy. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 13365 authors who have published 39516 publications receiving 1265601 citations. The organization is also known as: Universitá degli Studi di Perugia & Universita degli Studi di Perugia.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The discovery of bright gamma-ray emission coincident with supernova remnant (SNR) W51C is reported using the Large Area Telescope (LAT) on board the Fermi Gamma-ray Space Telescope as discussed by the authors.
Abstract: The discovery of bright gamma-ray emission coincident with supernova remnant (SNR) W51C is reported using the Large Area Telescope (LAT) on board the Fermi Gamma-ray Space Telescope. W51C is a middle-aged remnant (~10^4 yr) with intense radio synchrotron emission in its shell and known to be interacting with a molecular cloud. The gamma-ray emission is spatially extended, broadly consistent with the radio and X-ray extent of SNR W51C. The energy spectrum in the 0.2-50 GeV band exhibits steepening toward high energies. The luminosity is greater than 1x10^{36} erg/s given the distance constraint of D>5.5 kpc, which makes this object one of the most luminous gamma-ray sources in our Galaxy. The observed gamma-rays can be explained reasonably by a combination of efficient acceleration of nuclear cosmic rays at supernova shocks and shock-cloud interactions. The decay of neutral pi-mesons produced in hadronic collisions provides a plausible explanation for the gamma-ray emission. The product of the average gas density and the total energy content of the accelerated protons amounts to 5x10^{51}(D/6kpc)^2 erg/cm^3. Electron density constraints from the radio and X-ray bands render it difficult to explain the LAT signal as due to inverse Compton scattering. The Fermi LAT source coincident with SNR W51C sheds new light on the origin of Galactic cosmic rays.
302 citations
••
VU University Medical Center1, Cardiff University2, University of Navarra3, Brigham and Women's Hospital4, University of Oslo5, University of Milan6, University Health System7, Charité8, University of Brescia9, University of Michigan10, University of Göttingen11, University of Perugia12, Monash University13, University of Warwick14, Athens State University15, Northwestern University16, Boston University17, Campbell University18, Medical University of Graz19
TL;DR: To maximize the likelihood of identifying effective therapeutics for HF-PEF, lessons learned from the past decade of research should be applied to the design, conduct, and interpretation of future trials.
Abstract: The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly over the last two decades. In contrast, little or no progress has been made in identifying evidence-based, effective treatments for heart failure with preserved ejection fraction (HF-PEF). Despite the high prevalence, mortality, and cost of HF-PEF, large phase III international clinical trials investigating interventions to improve outcomes in HF-PEF have yielded disappointing results. Therefore, treatment of HF-PEF remains largely empiric, and almost no acknowledged standards exist. There is no single explanation for the negative results of past HF-PEF trials. Potential contributors include an incomplete understanding of HF-PEF pathophysiology, the heterogeneity of the patient population, inadequate diagnostic criteria, recruitment of patients without true heart failure or at early stages of the syndrome, poor matching of therapeutic mechanisms and primary pathophysiological processes, suboptimal study designs, or inadequate statistical power. Many novel agents are in various stages of research and development for potential use in patients with HF-PEF. To maximize the likelihood of identifying effective therapeutics for HF-PEF, lessons learned from the past decade of research should be applied to the design, conduct, and interpretation of future trials. This paper represents a synthesis of a workshop held in Bergamo, Italy, and it examines new and emerging therapies in the context of specific, targeted HF-PEF phenotypes where positive clinical benefit may be detected in clinical trials. Specific considerations related to patient and endpoint selection for future clinical trials design are also discussed.
302 citations
••
TL;DR: Protection from ozone in plants fumigated with isoprene may be due to a direct ozone quenching rather than to an induced resistance at membrane level, asrespective of the mechanism, isobrene is one of the most effective antioxidants in plants.
Abstract: Isoprene is formed in and emitted by plants and the reason for this apparent carbon waste is still unclear. It has been proposed that isoprene stabilizes cell and particularly chloroplast thylakoid membranes. We tested if membrane stabilization or isoprene reactivity with ozone induces protection against acute ozone exposures. The reduction of visible, physiological, anatomical, and ultrastructural (chloroplast) damage shows that clones of plants sensitive to ozone and unable to emit isoprene become resistant to acute and short exposure to ozone if they are fumigated with exogenous isoprene, and that isoprene-emitting plants that are sensitive to ozone do not suffer damage when exposed to ozone. Isoprene-induced ozone resistance is associated with the maintenance of photochemical efficiency and with a low energy dissipation, as indicated by fluorescence quenching. This suggests that isoprene effectively stabilizes thylakoid membranes. However, when isoprene reacts with ozone within the leaves or in a humid atmosphere, it quenches the ozone concentration to levels that are less or non-toxic for plants. Thus, protection from ozone in plants fumigated with isoprene may be due to a direct ozone quenching rather than to an induced resistance at membrane level. Irrespective of the mechanism, isoprene is one of the most effective antioxidants in plants.
302 citations
••
TL;DR: GP-BAR1 regulates intestinal barrier structure and expression increases in rodent models of colitis and Crohn's disease and ciprofloxacin is a GP-Bar1 ligand.
Abstract: Background
GP-BAR1, a member G protein coupled receptor superfamily, is a cell surface bile acid-activated receptor highly expressed in the ileum and colon. In monocytes, ligation of GP-BAR1 by secondary bile acids results in a cAMP-dependent attenuation of cytokine generation.
Aims
To investigate the role GP-BAR1 in regulating intestinal homeostasis and inflammation-driven immune dysfunction in rodent models of colitis.
Methods
Colitis was induced in wild type and GP-BAR1−/− mice by DSS and TNBS administration. Potential GP-BAR1 agonists were identified by in silico screening and computational docking studies.
Results
GP-BAR1−/− mice develop an abnormal morphology of colonic mucous cells and an altered molecular architecture of epithelial tight junctions with increased expression and abnormal subcellular distribution of zonulin 1 resulting in increased intestinal permeability and susceptibility to develop severe colitis in response to DSS at early stage of life. By in silico screening and docking studies we identified ciprofloxacin as a GP-BAR1 ligand. In monocytes, ciprofloxacin increases cAMP concentrations and attenuates TNFα release induced by TLR4 ligation in a GP-BAR1 dependent manner. Treating mice rendered colitic by TNBS with ciprofloxacin and oleanolic acid, a well characterized GP-BAR1 ligand, abrogates signs and symptoms of colitis. Colonic expression of GP-BAR1 mRNA increases in rodent models of colitis and tissues from Crohn's disease patients. Flow cytometry analysis demonstrates that ≈90% of CD14+ cells isolated from the lamina propria of TNBS-treated mice stained positively for GP-BAR1.
Conclusions
GP-BAR1 regulates intestinal barrier structure. Its expression increases in rodent models of colitis and Crohn's disease. Ciprofloxacin is a GP-BAR1 ligand.
302 citations
••
TL;DR: In this paper, the main results presented in literature are summarized, focusing on the processing behaviour and final properties of natural fibres with polymeric matrices (thermoplastics, thermosets and biodegradables).
Abstract: Natural abundance, much higher strength per unit weight than most inorganic fillers, lower density and their biodegradable nature make natural fillers attractive as reinforcements of engineering polymer systems. However, certain drawbacks such as incompatibility with the hydrophobic polymer matrix, the tendency to form aggregates during processing and poor resistance to moisture greatly reduce the potential of natural fibres to be used as reinforcements in polymers. In this review, the main results presented in literature are summarized, focusing on the processing behaviour and final properties of natural fibres with polymeric matrices (thermoplastics, thermosets and biodegradables) and paying attention to the use of physical and chemical treatments for the improvement of fibre-matrix interaction and composite mechanicaln properties. This work mainly focuses on the use of natural fibres for automotive applications.
301 citations
Authors
Showing all 13488 results
Name | H-index | Papers | Citations |
---|---|---|---|
Michael Grätzel | 248 | 1423 | 303599 |
Luigi Ferrucci | 193 | 1601 | 181199 |
Tobin J. Marks | 159 | 1621 | 111604 |
Johan Auwerx | 158 | 653 | 95779 |
Tony Pawson | 150 | 425 | 85196 |
Jack Hirsh | 146 | 734 | 86332 |
Alexander Belyaev | 142 | 1895 | 100796 |
R. L. McCarthy | 141 | 1238 | 115696 |
Harvey B Newman | 139 | 1594 | 88308 |
Guido Tonelli | 138 | 1458 | 97248 |
Elias Campo | 135 | 761 | 85160 |
Alberto Messineo | 134 | 1511 | 96492 |
Franco Ligabue | 134 | 1404 | 95389 |
Roberto Tenchini | 133 | 1390 | 94541 |
R. Bartoldus | 132 | 1624 | 97405 |